Disentangling shared genetic etiologies for kidney function and cardiovascular diseases

Jun Qiao,Kaixin Yao,Yujuan Yuan,Xichen Yang,Le Zhou,Yinqi Long,Miaoran Chen,Wenjia Xie,Yixuan Yang,Yangpo Cao,Siim Pauklin,Jinguo Xu,Yining Yang,Yuliang Feng

DOI: https://doi.org/10.1101/2024.07.26.24310191

2024-07-27

Abstract:Cardiovascular diseases (CVDs) are the leading cause of death worldwide, with chronic kidney disease (CKD) identified as a significant risk factor. CKD is primarily monitored through the estimated glomerular filtration rate (eGFR), calculated using the CKD-EPI equation. Although epidemiological and clinical studies have consistently demonstrated strong associations between eGFR and CVDs, the genetic underpinnings of this relationship remain elusive. Recent genome-wide association studies (GWAS) have highlighted the polygenic nature of these conditions and identified several risk loci correlating with their cross-phenotypes. Nonetheless, the extent and pattern of their pleiotropic effects have yet to be fully elucidated. We analyzed the most comprehensive GWAS summary statistics, involving around 7.5 million individuals, to investigate the shared genetic architectures and the underlying mechanisms between eGFR and CVDs, focusing on single nucleotide polymorphisms (SNPs), genes, biological pathways, and proteins exhibiting pleiotropic effects. Our study identified 508 distinct genomic locations associated with pleiotropic effects across multiple traits, involving 379 unique genes, notably L3MBTL3 (6q23.1), MMP24 (20q11.22), and ABO (9q34.2). Additionally, pathways such as stem cell population maintenance and the glutathione metabolism pathway were pivotal in mediating the relationships between these traits. From the perspective of vertical pleiotropy, our findings suggest a causal relationship between eGFR and conditions such as atrial fibrillation and venous thromboembolism. These insights significantly enhance our understanding of the genetic links between eGFR and CVDs, potentially guiding the development of novel therapeutic strategies and improving the clinical management of these conditions.

Genetic and Genomic Medicine

What problem does this paper attempt to address?

This paper aims to explore the shared genetic basis between renal function (represented by estimated glomerular filtration rate, eGFR) and cardiovascular diseases (CVDs) and their underlying mechanisms. Specifically, the study attempts to address the following key issues:

1. **Shared genetic architecture**: The study aims to quantify the overall and local genetic correlations between eGFR and six major cardiovascular diseases (atrial fibrillation AF, coronary artery disease CAD, venous thromboembolism VTE, heart failure HF, peripheral artery disease PAD, and stroke) and explore the genetic overlap between them.

2. **Pleiotropy analysis**: The study hopes to detect horizontal and vertical pleiotropy among these traits through single - nucleotide polymorphism (SNP) - level analysis to identify possible causal relationships and common - cause effects.

3. **Gene and pathway analysis**: The study also attempts to identify pleiotropic genes through gene mapping and expression quantitative trait locus (eQTL) mapping and conduct biological pathway enrichment analysis to elucidate the biological functions of these genes in multiple effector loci.

4. **Protein - level analysis**: The study further explores the potential association between plasma protein levels and disease susceptibility and evaluates its potential as a treatment target.

5. **Mendelian randomization analysis**: Through Mendelian randomization (MR) analysis, the study attempts to estimate the bidirectional causal relationships between eGFR and cardiovascular diseases and consider the effects of confounding factors and sample overlap.

In summary, through comprehensive analysis of genomic data, this paper aims to reveal the complex genetic interactions between eGFR and cardiovascular diseases, providing new insights and potential treatment targets for future research and clinical management.